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1. INTRODUCTION {#dom14024-sec-0001}
===============

Type 2 diabetes mellitus (T2DM) is associated with an increased cardiovascular disease (CVD) risk. The underlying pathogenesis of CVD in T2DM is incompletely understood. Recent data suggest that the enzyme dipeptidyl peptidase‐4 (DPP‐4) constitutes a link between T2DM and cardiovascular (CV) risk.[^1^](#dom14024-bib-0001){ref-type="ref"}

Several pathways involved in CVD may be targeted by inhibiting DPP‐4. This changes the proportion of lymphocyte subpopulations[2](#dom14024-bib-0002){ref-type="ref"}, [3](#dom14024-bib-0003){ref-type="ref"} and degrades multiple chemokines, such as stromal cell‐derived factor 1α (SDF‐1α, also known as CXCL12) and chemokine (C‐C motif) ligand 5 (CCL5), and blocks binding to their major receptors CXCR4 and CCR5, respectively.[^4^](#dom14024-bib-0004){ref-type="ref"} These chemokines are involved in the production of progenitor cells in the bone marrow, including endothelial progenitor cells (EPCs) that facilitate endothelial cell function.[^5^](#dom14024-bib-0005){ref-type="ref"} Additionally, a recently discovered subpopulation of T cells, angiogenic T (Tang) cells, constitute the central cell cluster of EPC colonies[^6^](#dom14024-bib-0006){ref-type="ref"} and cooperate with EPCs to facilitate vascular repair.[^7^](#dom14024-bib-0007){ref-type="ref"} Tang cells enhance the differentiation of early EPCs and promote neovascularization and endothelial repair, possibly through the secretion of proangiogenic cytokines, such as vascular endothelial growth factor (VEGF), interleukin (IL)‐8 and matrix metalloproteinases.[^6^](#dom14024-bib-0006){ref-type="ref"} Tang cells are characterized by co‐expression of CD31 and CXCR4, and are heterogeneous, since they may express CD4 or CD8, and can co‐express naïve and memory markers.[^7^](#dom14024-bib-0007){ref-type="ref"}

Since CXCR4 is the receptor for SDF‐1α, we hypothesized that DPP‐4 inhibition may increase the frequency of circulating Tang cells. Therefore, we determined the frequency of circulating Tang cells in treatment‐naive people with T2DM compared with healthy controls, and assessed the effect of 26 weeks of DPP‐4 inhibition on the frequency of Tang cells and EPCs. The effect of DPP‐4 inhibition on circulating levels of SDF‐1α, VEGF and IL‐8 was also determined.

2. METHODS {#dom14024-sec-0002}
==========

2.1. Study design and population {#dom14024-sec-0003}
--------------------------------

Samples included in this study were from the RELEASE trial (NCT02015299). The study design and selection of participants have been discussed previously.[^8^](#dom14024-bib-0008){ref-type="ref"} Participants were randomized in a 1:1 ratio to Linagliptin 5 mg once daily or a matching placebo for 26 weeks, stratified by age (30--49 vs. 50--70 years). Additionally, a group of 19 healthy controls was included for measurement of Tang cells. Healthy controls did not have diabetes, obesity or CVD and were of similar age. Following the direct assessment of standard clinical laboratory variables, peripheral blood mononuclear cells (PBMCs) were isolated and stored in liquid nitrogen for determination of Tang cell levels, and plasma was obtained from heparinized blood.

2.2. Tang cell analysis at inclusion and at 26 weeks {#dom14024-sec-0004}
----------------------------------------------------

Frequencies of CD4^+^ and CD8^+^ Tang cell populations were analysed in thawed PBMCs by flow cytometry. Briefly, cells were incubated with anti‐CD3‐PerCP, anti‐CD8‐AF700, anti‐CD25‐PE, anti‐CD45Ro‐FITC, anti‐CCR7PE‐Cy7, anti‐CD31‐PB and anti‐CXCR4‐BV605 (Biolegend, San Diego and BD Biosciences, Vianen, Netherlands). Samples were analysed on a BD™ LSR II flow cytometer and plotted using Kaluza v1.2 (Beckman Coulter). Tang cells were expressed as percentages of total T cells (CD3^+^) or as percentage of total CD4^+^(gated as CD3^+^CD8^−^ population) or of total CD8^+^ cells (see Figure [S1](#dom14024-supitem-0001){ref-type="supplementary-material"} for gating strategy). Based on the expression of the surface molecules CCR7 and CD45Ro, a distinction was made in naive, central memory (CM), effector memory (EM) and terminally differentiated (TD) cell populations for both CD4^+^ and CD8^+^ subsets.

2.3. EPC analysis at inclusion and at 26 weeks {#dom14024-sec-0005}
----------------------------------------------

For the EPC analysis 200 μL lithium‐heparin blood was incubated with anti‐CD34‐PE (clone 581; IQproducts), anti‐CD133‐APC (clone AC133; Miltenyi Biotec) and anti‐KDR/VEGFR‐FITC (KDR‐FITC; R&D systems) or appropriate isotype controls (see Figure S[1](#dom14024-supitem-0001){ref-type="supplementary-material"} for gating strategy). Flow cytometry measurements were performed on a BD Bioscience FACS Calibur flow cytometer, and analysed using Kaluza analysis software.

2.4. Enzyme‐linked immunosorbent assay {#dom14024-sec-0006}
--------------------------------------

Circulating levels of C‐reactive protein, IL‐8, VEGF and SDF‐1α were measured in plasma samples with Duosets enzyme‐linked immunosorbent assays (R&D Systems) according to the manufacturer\'s instructions.

2.5. Statistical methods {#dom14024-sec-0007}
------------------------

Means or medians were compared with independent sample Student *t*‐tests or Mann--Whitney *U*‐tests, as appropriate, and discrete variables using chi‐squared or Fisher\'s exact tests. An ANCOVA model was constructed with change from baseline (ie, Tang cell percentages or EPC levels) as a dependent variable, randomization group as fixed factor and baseline levels as covariate. Variables were log transformed when distribution was non‐parametric. All analyses were performed with SPSS (2013. IBM SPSS Statistics, Version 22.0). *P* values of \<0.05 were taken to indicate statistical significance.

3. RESULTS {#dom14024-sec-0008}
==========

Forty‐five of the 50 screened participants with T2DM were randomized, 44 started treatment, and cell isolation was possible in 41 participants (20 Linagliptin, 21 placebo). The median \[interquartile range (IQR)\] age was 63 \[56--67\] years, median \[IQR\] BMI was 30.4 \[27.4--37.2\] kg/m^2^, median \[IQR\] diabetes duration was 1 \[0--3.5\] years and the mean (SD) glycated haemoglobin (HbA1c) level was 45 (±4.8) mmol/mol. Baseline characteristics were well balanced between groups. More baseline characteristics can be found in the paper by De Boer et al.[^8^](#dom14024-bib-0008){ref-type="ref"} The median \[IQR\] age in the healthy control group (n = 19, 63% male) was 56 \[44--67\] years.

Circulating Tang cell levels were significantly lower in people with T2DM (median \[IQR\] 11.5 \[9.4--17.8\]%) compared with healthy controls (median \[IQR\] 20.4 \[16.6--27.3\]%; *P* \< 0.001 \[Figure [1A](#dom14024-fig-0001){ref-type="fig"}\]). This was also seen in CD4^+^ T‐cell subsets (median \[IQR\] 7.7 \[4.3--10.8\]%) versus healthy controls (median \[IQR\] 13.2 \[8.7--20.2\]%; *P* \< 0.01) and in CD8^+^ T‐cell subsets (median \[IQR\] 26.7 \[19.4--38.1\]% vs. 46.5 \[32.1--55.2\]%; *P* \< 0.001 \[Figure [1B,C](#dom14024-fig-0001){ref-type="fig"}\]). There were no differences between the T2DM and the healthy control group regarding percentages CD4^+^‐naive, EM and TD populations, while percentage of CM cells was higher in people with T2DM (*P* = 0.02; Table [1](#dom14024-tbl-0001){ref-type="table"}). There were significantly lower numbers of CD8^+^‐naive cells in people with T2DM compared to healthy controls (*P* = 0.005). Tang cells were specifically present in naive fractions of both CD4^+^ cells and CD8^+^cells. In people with T2DM, percentages of Tang cells were reduced in the EM fraction of both CD4^+^ cells and CD8^+^cells (Table [1](#dom14024-tbl-0001){ref-type="table"}).

![Frequencies of circulating Tang cells (CD31^+^, CXCR4^+^) in healthy controls (HC) and people with type 2 diabetes mellitus (T2DM) in **A,** CD3^+^ cells and in **B**, CD4^+^ and **C,** CD8^+ ^subsets measured by flow cytometry. Frequencies of circulating CD3^+^ Tang cells in people with type 2 diabetes mellitus (T2DM) before and after 26‐week treatment with Linagliptin in D or with placebo in E. V1 = visit 1, baseline; V2 = visit 2, week 26](DOM-22-1220-g001){#dom14024-fig-0001}

###### 

Percentages of T cells, CD4^+^ and CD8^+^ cells, subsets within CD4^+^ cells and CD8^+^ cells, and percentages of angiogenic T cells within these subsets

                                         Healthy control group, % Median \[IQR\]   T2DM group, % Median \[IQR\]   *P*
  ---------------- --------------------- ----------------------------------------- ------------------------------ ---------
  **T cells**                            73.3 \[63.3--75.9\]                       69.8 \[62.3--77.3\]            0.878
  CD4^+^ cells                           50.0 \[42.1--57.3\]                       47.8 \[41.0--53.0\]            0.378
  CD4^+^           Naive                 39.2 \[29.5--49.3\]                       36.0 \[23.6--44.4\]            0.242
  CM               23.2 \[17.1--32.7\]   30.8 \[22.8--38.4\]                       0.020                          
  EM               26.7 \[19.2--37.9\]   25.2 \[18.1--38.4\]                       0.612                          
  TD               4.9 \[2.8--7.3\]      3.8 \[2.2--6.3\]                          0.343                          
  CD8^+^ cells                           14.2 \[11.4--20.4\]                       17.2 \[11.7--24.9\]            0.325
  CD8^+^           Naive                 32.0 \[21.5--41.6\]                       17.6 \[11.1--27.8\]            0.005
  CM               4.8 \[3.0--6.0\]      6.8 \[4.3--9.3\]                          0.112                          
  EM               29.3 \[23.0--37.1\]   33.0 \[25.3--41.6\]                       0.167                          
  TD               27.2 \[19.0--40.8\]   36.5 \[22.0--43.0\]                       0.172                          
  **Tang cells**                         20.4 \[16.6--27.3\]                       11.2 \[9.4--17.8\]             \<0.001
  CD4^+^ cells                           13.2 \[8.7--20.2\]                        7.7 \[5.3--10.8\]              \<0.01
  CD4^+^           Naive                 10.4 \[4.8--30.9\]                        15.8 \[9.2--28.2\]             0.409
  CM               3.4 \[2.5--8.0\]      3.7 \[2.3--5.9\]                          0.437                          
  EM               4.8 \[2.0--20.0\]     1.6 \[1.0--2.7\]                          0.0002                         
  TD               9.5 \[6.6--14.1\]     8.2 \[3.7--11.2\]                         0.143                          
  CD8^+^ cells                           46.5 \[32.1--55.2\]                       27.7 \[19.4--38.1\]            \<0.001
  CD8^+^           Naive                 53.2 \[28.4--85.6\]                       66.7 \[51.1--78.4\]            0.437
  CM               21.9 \[12.1--30.7\]   18.2 \[12.6--25.8\]                       0.387                          
  EM               19.7 \[12.9--65.2\]   6.9 \[4.8--11.5\]                         \<0.0001                       
  TD               10.6 \[8.4--12.7\]    5.4 \[3.3--7.4\]                          0.0003                         

Abbreviations: CM, central memory; EM, effector memory; IQR, interquartile range; TD, terminally differentiated; Tang cells, angiogenic T‐cells; T2DM, type 2 diabetes mellitus.

The frequency of total Tang cells (CD3^+^) increased in the Linagliptin‐treated (*P* = 0.029) but remained stable in the placebo‐treated participants (Figure [1D,E](#dom14024-fig-0001){ref-type="fig"}). The change from baseline differed significantly between Linagliptin and placebo (median \[IQR\] +1.58 \[--0.36 to 2.63\]% vs. --0.24 \[--0.74 to 0.52\]%; *P* = 0.016). After adjustment for baseline total Tang cells, the trend remained present (*P* = 0.098). A similar increasing trend was seen for CD8^+^ Tang cells (*P* = 0.052), but not for CD4^+^ Tang cells (*P* =0.41). There were no significant changes in T‐cell subsets or Tang cells within these subsets after Linagliptin treatment and placebo (data not shown). The change in the frequency of Tang cells in Linagliptin‐treated people with T2DM correlated negatively with change in HbA1c (ρ = 0.39, *P* = 0.020); this was not observed with placebo. Concomitantly, a rise in SDF‐1α levels (median \[IQR\] 180 \[126--238\] pg/mL vs. 0 \[0--2\] pg/mL; *P* \< 0.001 compared to placebo) was seen in Linagliptin‐ compared to placebo‐treated participants (Figure S[2](#dom14024-supitem-0001){ref-type="supplementary-material"}). No differences in levels of IL‐8 and VEGF were observed after Linagliptin or placebo treatment (data not shown).

A non‐significant change after Linagliptin treatment was seen in levels of EPCs (CD34^+^CD133^+^KDR^+^; *P* = 0.089) but was not seen for placebo (Figure S3A). There was no correlation with Tang levels at baseline (data not shown). EPC numbers from people with T2DM at baseline correlated negatively with plasma levels of IL‐8 (Spearman ρ = −0.407, *P* = 0.008), and VEGF (ρ = −0.412, *P* = 0.008), and C‐reactive protein (ρ = −0.319, *P* = 0.043; Figure S3B).

4. DISCUSSION {#dom14024-sec-0009}
=============

In the present study we showed that levels of Tang cells were significantly reduced in treatment‐naive people with T2DM compared to age‐ and sex‐matched healthy controls. Tang cells are particularly found in naive subsets of both CD4^+^ cells and CD8^+^cells. After 26 weeks of treatment with the DPP‐4 inhibitor Linagliptin, a remarkable rise in levels of SDF‐1α was observed, coinciding with a significant increase in CD3^+^ Tang cells and a trend for both CD4^+^ and CD8^+^ Tang cells, while Tang cells remained unchanged in placebo.

Tang cells are required for colony formation and differentiation of early EPCs[^6^](#dom14024-bib-0006){ref-type="ref"} and, therefore, play an important role in endothelial repair. Tang cells were found to be reduced in hypertension‐related cerebral small vessel disease[^9^](#dom14024-bib-0009){ref-type="ref"} and in people with active rheumatoid arthritis.[^7^](#dom14024-bib-0007){ref-type="ref"} By contrast, levels were not reduced in people with systemic lupus erythematosus, only in the disease controls, that is, people with rheumatoid arthritis and people with CV risk factors,[^10^](#dom14024-bib-0010){ref-type="ref"} and were increased in lupus nephritis in a later study.[^11^](#dom14024-bib-0011){ref-type="ref"} Miao et al [^12^](#dom14024-bib-0012){ref-type="ref"} did observe increased CD8^+^ Tang cell levels in people with systemic lupus erythematosus, but not CD4^+^ Tang or total CD3^+^ Tang cells. These data underline the complexity of Tang cells and suggest that several diseases affect Tang cell levels.

Interestingly, we did not observe a correlation between levels of Tang cells and EPCs. The loss of association between these two angiogenic bone marrow‐derived cells may indicate a disruption of angiogenic repair by multiple disease‐related processes, such as oxidative stress and hyperglycaemia.[^13^](#dom14024-bib-0013){ref-type="ref"}

The only other intervention study on Tang cell levels was in people with rheumatoid arthritis[,^14^](#dom14024-bib-0014){ref-type="ref"} in which Tang cells increased significantly after TNF‐α blockade treatment, especially in those people responding well to therapy.[^14^](#dom14024-bib-0014){ref-type="ref"} Our results, although obtained with a completely different intervention, seem to be in line. Tang cell levels increased following Linagliptin treatment and their rise correlated negatively with HbA1c reduction. This supports the hypothesis that interventions on disease control stimulate bone‐marrow Tang cell recruitment, which may potentially have a beneficial effect on endothelial repair.

The effects of DPP‐4 inhibitors on EPC levels have been investigated previously. A 4‐day study with Linagliptin increased EPC levels in people with T2DM,[^15^](#dom14024-bib-0015){ref-type="ref"} while 12‐week treatment did not affect EPC levels.[^16^](#dom14024-bib-0016){ref-type="ref"} In the first study, EPCs were defined as CD34^+^ CD133^+^ or CD34^+^ KDR^+^, while in the second study EPCs were defined as CD34^+^ CD133^+^KDR^+^, as in the present study. Consequently, the duration, as well as gating strategy could have played a role in the neutral effect of Linagliptin in the present study and underlines the importance of measuring EPCs by standardized markers. As mentioned, IL‐8 and VEGF levels were negatively correlated to EPC levels at baseline in people with T2DM, and both IL‐8 and VEGF levels were not changed after Linagliptin treatment as well. We did see an increase in SDF‐1α levels in the Linagliptin‐treated participants.

The present study has some limitations. First, the duration of treatment was 6 months, so whether long‐term changes would be sustained or even be of a larger magnitude is unknown. Additionally, it is unclear whether an increase in Tang cell levels would also result in a significant reduction of CV events. Second, the trial lacked an active control group, so whether Tang cell levels would increase after treatment with other anti‐hyperglycaemic drugs is also unclear. Furthermore, we included recently diagnosed people with T2DM so it might not be possible to extrapolate the findings to those with a longer diabetes duration or with advanced atherosclerotic disease.

In conclusion, Tang cell levels are decreased in people with T2DM, and Linagliptin stimulates recruitment of these cells. This might indicate the value of DPP‐4 inhibitor treatment in the course of T2DM in repairing endothelial damage of the micro‐ and microvasculature.
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###### 

**Figure S1.** Gating strategy for determination of angiogenic T cells (Tang) in peripheral blood mononuclear cells (PBMCs). Lymphocytes were gated for analysis based on forward and side scatter properties. Positively and negatively stained populations were calculated by quadrant dot‐plot analysis, determined by the appropriate isotype controls. Data were collected for 1 × 10^6^ events for each sample Measurement of Tang starts by gating lymphocytes from PBMC fraction, next gating of CD4^+^ and CD8^+^ T cell subsets. With help of specific anti‐CXCR4 and anti‐CD31 antibodies and isotype controls percentages of Tang cells can be determined in total T cells (CD3^+^) and in CD4^+^and CD8^+^ T cell subsets.

**Figure S2.** Plasma SDF‐1α levels in people with type 2 diabetes mellitus (T2DM) before and after 26 week treatment with Linagliptin or placebo. V1 = visit 1, baseline; V2 = visit 2, week 26

**Figure S3.** Whole blood EPC levels (CD34^+^CD133^+^KDR^+^). EPC level changes in Linagliptin and placebo treated people with T2DM (A) and association between EPC numbers at baseline with plasma levels of C‐reactive protein (CRP), interleukin 8 (IL‐8) and vascular endothelial growth factor (VEGF) (B).

###### 

Click here for additional data file.
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